Hepatocellular and extrahepatic cancer in patients with autoimmune hepatitis - A long-term follow-up study in 634 Swedish patients

Scandinavian Journal of Gastroenterology

Volumn 50, Issue 2, 2015, Pages 217-223

  Borssén, Åsa Danielsson ^a   Almer, Sven ^b   Prytz, Hanne ^c   Wallerstedt, Sven ^d   Friis Liby, Inga Lill ^d   Bergquist, Annika ^b   Nyhlin, Nils ^e   Hultcrantz, Rolf ^b   Sangfelt, Per ^f   Weiland, Ola ^b   Lindgren, Stefan ^c   Verbaan, Hans ^c   Werner, Mårten ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Autoimmune hepatitis; Autoimmune liver disease; Cancer; Extrahepatic cancer; Hepatocellular carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; BILE DUCT CARCINOMA; CANCER INCIDENCE; CANCER PATIENT; CANCER REGISTRY; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NON MELANOMA SKIN CANCER; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; SWEDISH CITIZEN; CARCINOMA, HEPATOCELLULAR; HEPATITIS, AUTOIMMUNE; INCIDENCE; LIVER NEOPLASMS; MIDDLE AGED; REGISTER; RISK FACTOR; SKIN NEOPLASMS; SWEDEN;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS, AUTOIMMUNE; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; REGISTRIES; RISK FACTORS; SKIN NEOPLASMS; SWEDEN;

EID: 84921377866     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2014.983154     Document Type: Article

References (34)

1. Heneghan MA, Yeoman AD, Verma S, Smith AD, Longhi MS. Autoimmune hepatitis. Lancet 2013;382: 1433-44.
2. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998;33:99-103.
3. Werner M, Prytz H, Ohlsson B, Almer S, Bjornsson E, Bergquist A, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008;43:1232-40.
4. Gronbaek L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol 2014;60:612-17.
5. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer Journal Clin 2005;55:74-108.
6. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35-50.
7. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
8. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
9. European Association for Study of Liver; European Organisation for Research and Treatment of Cancer. EASL - EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 2012;48:599-641.
10. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with child-pugh class A cirrhosis. Am J Med 1996;101:422-34.
11. Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 2002;35:75-81.
12. Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol 2008;103:1944-51.
13. Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening. Hepatology 2008;48:863-70.
14. Teufel A, Weinmann A, Centner C, Piendl A, Lohse AW, Galle PR, et al. Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol 2009;15:578-82.
15. Wang KK, Czaja AJ. Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis. Hepatology 1988;8:1679-83.
16. Park SZ, Nagorney DM, Czaja AJ. Hepatocellular carcinoma in autoimmune hepatitis. Dig Dis Sci 2000;45:1944-8.
17. Hino-Arinaga T, Ide T, Kuromatsu R, Miyajima I, Ogata K, Kuwahara R, et al. Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1. J Gastroenterol 2012;47:569-76.
18. Werner M, Almer S, Prytz H, Lindgren S, Wallerstedt S, Bjornsson E, et al. Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol 2009;50:388-93.
19. Ngu JH, Gearry RB, Frampton CM, Stedman CA. Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology 2012;55:522-9.
20. Czaja AJ. Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci 2013;58:1459-76.
21. Zimmermann T, Hoppe-Lotichius M, Tripkovic V, Barreiros AP, Wehler TC, Zimmermann A, et al. Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for post-transplant lymphoproliferative disease (PTLD). Eur J Intern Med 2010;21:208-15.
22. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004;23:6524-34.
23. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
24. Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 2009;48:27-33.
25. Bortfall och kvalitet. The National Board of Health and Welfare. Available from http://www.socialstyrelsen.se/register/ dodsorsaksregistret/bortfallochkvalitet.
26. Causes of Death 2012. Socialstyrelsen. 2012. Available from http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/19175/2013-8-6.pdf. Cited August 2013.
27. Trinchet JC. Hepatocellular carcinoma in 2014: Current situation and future prospects. Diagn Interv Imaging 2014; 95:705-8.
28. Levercellscancer Nationellt va˚rdprogram 2012. Regionala Cancercentrum i Samverkan. 2012. Available from http://www.cancercentrum.se/PageFiles/5444/NatVP-levercellscancer- 20120701-fullst%C3%A4ndig.pdf. Cited 1 July 2013.
29. Maddox JS, Soltani K. Risk of nonmelanoma skin cancer with azathioprine use. Inflamm Bowel Dis 2008;14: 1425-31.
30. Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lemann M, Cosnes J, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-25.
31. Leung J, Dowling L, Obadan I, Davis J, Bonis PA, Kaplan MM, et al. Risk of non-melanoma skin cancer in autoimmune hepatitis. Dig Dis Sci 2010;55:3218-23.
32. Roman E, Smith AG. Epidemiology of lymphomas. Histopathology 2011;58:4-14.
33. Beaugerie L. Lymphoma: the bete noire of the long-term use of thiopurines in adult and elderly patients with inflammatory bowel disease. Gastroenterology 2013;145:927-30.
34. Cancer incidence in Sweden 2009. Socialstyrelsen. 2010. Available from http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/18204/2010-12-17.pdf.cited 10 December 2010.